Methods and compositions of novel triazine compounds

1. A compound having the formula:

or a salt, a diastereomeric mixture, an enantiomer, a tautomer, or a racemic mixture thereof; wherein:

G is NH or NMe;

E is N or CH;

X 1 is selected from m-F, m-Cl, m-Br, m-l, m-NO 2 , m-CN, m-CF 3 , m-C(O)OEt, or m-C(O)ONa;

X 2 is selected from p-OCH 3 , p-OEt, p-O-n-Pr, p-O-i-Pr, p-OCF 3 , p-OC(O)Me, p-NH 2 , p-NHMe, p-NMe 2 , p-Me, p-Et, p-OH, p-ONa, p-OP(O)(OH) 2 , p-OCH 2 OP(O)(OH) 2 , p-OCH 2 OP(O)(OH)(ONa), p-OCH 2 OP(O)(O-t-Bu) 2 , p-OCH 2 OP(O)(OCH 2 Ph) 2 , p-OCH 2 SMe, p-OCH 2 OMe, p-O(CH 2 CH 2 O) 3 CH 2 CH 2 OH, p-OC(O)(CH 2 CH 2 O) 4 CH 2 CH 2 OH, or p-OC(O)(CH 2 CH 2 O) 4 CH 2 CH 2 OMe,

R 1 is H;

z is 0, 1, or 2;

either: a) A is NH or NMe, and Y 1 is selected from

or b) AY 1 in combination is selected from

either: a) D is NH, NMe, or O, and Y 2 is selected from —H,

or b) DY 2 in combination is selected from

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claim 1 .

3. The pharmaceutical composition as claimed in claim 2 , further comprising:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

4. The pharmaceutical composition as claimed in claim 2 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

5. A compound having the formula:

or a salt, a diastereomeric mixture, an enantiomer, a tautomer, or a racemic mixture thereof; wherein:

R 1a is selected from

R 6a is selected from H or Me;

R x is selected from

wherein R 2a is selected from H or Me; and

R 3a is selected from H,

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claim 5 .

7. The pharmaceutical composition as claimed in claim 6 , further comprising:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

8. The pharmaceutical composition as claimed in claim 6 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

9. A compound having the formula:

or a salt, a diastereomeric mixture, an enantiomer, a tautomer, or a racemic mixture thereof; wherein:

R 1a is selected from

R 7a is selected from

wherein R 4a is selected from H or Me; and

R 5a is selected from

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claim 9 .

11. The pharmaceutical composition as claimed in claim 10 , further comprising:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

12. The pharmaceutical composition as claimed in claim 10 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

13. A compound having the formula:

or a salt, a diastereomeric mixture, an enantiomer, a tautomer, or a racemic mixture thereof; wherein:

R 1a is selected from

R 2a is selected from

R 3a is selected from —H,

R 5a is selected from

R 6a is selected from —H or —CH 3 .

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claim 13 .

15. The pharmaceutical composition as claimed in claim 14 , further comprising:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

16. The pharmaceutical composition as claimed in claim 14 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

17. A compound selected from:

N-(4-benzyloxy-3-chloro-phenyl)-N′-cycloheptyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N-(4-benzyloxy-3-chloro-phenyl)-N′-cycloheptyl-N″-methyl-N″-piperidin-4-yl-[1,3,5]triazine-2,4,6-triamine,

4-[4-cycloheptylamino-6-(methyl-piperidin-4-yl-amino)-[1,3,5]triazin-2-ylamino]-phenol,

4-{4-cycloheptylamino-6-[methyl-(1-methyl-piperidin-4-yl)-amino]-1,3,5]triazin-2-ylamino}-phenol,

2-chloro-4-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-phenol,

2-chloro-4-(4-chloro-6-cycloheptylamino-[1,3,5]triazin-2-ylamino)-phenol,

N-(1-benzyl-piperidin-4-yl)-N′-(3-fluoro-4-methoxy-phenyl)-N″-cycloheptyl-[1,3,5]triazine-2,4,6-diamine,

N-cycloheptyl-N′-(4-methoxy-phenyl)-N″-piperidin-4-yl-[1,3,5]triazine-2,4,6-triamine,

6-chloro-N-cyclopropyl-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-cyclopropyl-N′-(3-flouro-4-methoxy-phenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N-cyclopropyl-N′-(1-ethyl-pyrrolidin-2-ylmethyl)-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine,

6-chloro-N-(3-chloro-4-methoxyphenyl)-N′-cyclopropyl-[1,3,5]triazine-2,4-diamine,

N-cyclopropyl-N′-(3-chloro-4-methoxyphenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

6-chloro-N,N′-bis-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-(1-ethyl-pyrrolidin-2-ylmethyl)-N′,N″-bis-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine,

1-[4-(3-chloro-4-methoxyanilino)-cycloheptyl amino-1,3,5-triazin-2-yl]-2-azoloamymethanol,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(4-methylpiperzino)-1,3,5-triazine-4,2-diamine,

3-[4-(3-chloro-4-methoxyanilino)-6-cycloheptylamino-1,3,5-triazin-2-yloxy]-2-ethyl-4H-4-pyranone,

1-[3-{4-(3-chloro-4-methoxyanilino)-6-cycloheptylamino-1,3,5-triazine-2-yloxy}piperidino]-1-ethanone,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-isopropoxy-1,3,5-triazine-2,4-diamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(2-azolanylmethoxy)-1,3,5-triazine-2,4-diamine,

1-[4-(3-chloro-4-methoxy-phenylamino)-6-cycloheptylamino-[1,3,5]triazine-2-yl]-piperidin-3-ol],

1-[4-(3-chloro-4-methoxy-phenylamino)-6-cycloheptylamino-[1,3,5]triazine-2-yl]-piperidin-4-ol],

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(1-methyl-2-azolanylmethoxy)-1,3,5-triazine-2,4-diamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(1-methyl-4-piperidyloxy)-1,3,5-triazine-2,4-diamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(1,4-thiazinan-4-yl)-1,3,5-triazine-4,2-diamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(2-fluorophenoxy)-1,3,5-triazine-4,2-diamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-[2-(2-fluorophenoxy) ethoxy]-1,3,5-triazine-4,2-diamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-6-(6-methyl-2-pyryl methoxy]-1,3,5-triazine-4,2-diamine,

N-(3-chloro-4-methoxyphenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl piperidin-4-yl)[1,3,5]triazine-2,4,6-triamine,

N-(3-chloro-4-methoxyphenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl piperidin-4-yl)[1,3,5]triazine-2,4,6-triamine, HCl salt,

6-methoxy-N-(3-Chloro-4-methoxy phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4 diamine,

6-ethoxy-N-(3-Chloro-4-methoxy phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4 diamine,

6-isopropoxy-N-(3-Chloro-4-methoxy phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4 diamine,

N-(3-chloro-4-methoxyphenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl piperidin-4-yl)[1,3,5]triazine-2,4,6-triamine,

6-chloro-N-(3-chloro-4-methoxy-phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4-diamine,

(3-chloro-4-methoxy-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine,

6-Chloro-N-(3-fluoro-4-methoxy-phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4-diamine, or

(3-fluoro-4-methoxy-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine.

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and according to claim 17 .

19. The pharmaceutical composition as claimed in claim 18 , further comprising:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

20. The pharmaceutical composition as claimed in claim 18 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

21. A compound selected from:

22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claim 21 .

23. The pharmaceutical composition as claimed in claim 22 , further comprising:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

24. The pharmaceutical composition as claimed in claim 22 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.